Longeveron (LGVN) Retained Earnings (2021 - 2026)
Longeveron (LGVN) posted quarterly Retained Earnings of $153.0 million for Q1 2026, up 233.55% year-over-year from $45.9 million in Q1 2025, and up 10.93% quarter-over-quarter from $138.0 million in Q4 2025.
Longeveron (LGVN) Retained Earnings (2021 - 2026) Analysis & Trends
Longeveron's Retained Earnings history runs 6 years deep, the most recent figure standing at $153.0 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 233.55% year-over-year to $153.0 million; the TTM figure through Mar 2026 stood at $153.0 million (up 233.55% YoY), while the FY2025 annual figure was $138.0 million, up 4.93% from the prior year.
- Retained Earnings for Q1 2026 stood at $153.0 million, up from $138.0 million in the prior quarter.
- The five-year high for Retained Earnings was $153.0 million in Q1 2026, with the low at -$126.9 million in Q3 2025.
- The 5-year median for Retained Earnings is -$39.7 million (2022), against an average of -$9.6 million.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings sank 23705.04% in 2023, then soared 13228900.0% in 2025.
- Longeveron's Retained Earnings stood at -$357000.0 in 2022, then tumbled by 23705.04% to -$85.0 million in 2023, then surged by 254.71% to $131.5 million in 2024, then increased by 4.93% to $138.0 million in 2025, then grew by 10.93% to $153.0 million in 2026.
- Business Quant data shows LGVN's Retained Earnings at $153.0 million in Q1 2026, $138.0 million in Q4 2025, and -$126.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 153.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153.49 Mn |
| Mar 31, 2026 | 153.04 Mn |
| Dec 31, 2025 | 137.96 Mn |
| Sep 30, 2025 | -126.87 Mn |
| Jun 30, 2025 | 132.29 Mn |
| Mar 31, 2025 | -114.60 Mn |
| Dec 31, 2024 | 131.48 Mn |
| Sep 30, 2024 | -105.53 Mn |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -89.04 Mn |
| Dec 31, 2023 | -84.98 Mn |
| Sep 30, 2023 | -78.96 Mn |
| Jun 30, 2023 | -335,000.00 |
| Mar 31, 2023 | -89.00 Mn |
| Dec 31, 2022 | -357,000.00 |
| Dec 31, 2021 | 81.47 Mn |